Hinova Pharmaceuticals (SH:688302)2026-02-27 09:00Financial Performance - The total operating revenue for 2025 was RMB 20.67 million, a significant increase of 5,535.71% compared to RMB 0.3668 million in the previous year[4] - The net profit attributable to the parent company was a loss of RMB 136.69 million, an improvement of RMB 62.81 million compared to a loss of RMB 199.50 million in the previous year[6] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was a loss of RMB 167.37 million, an improvement of RMB 50.14 million compared to a loss of RMB 217.51 million in the previous year[6] - The company’s basic earnings per share for 2025 were -RMB 1.38, compared to -RMB 2.01 in the previous year[4] - The company’s weighted average return on net assets was -12.12%, an improvement from -15.59% in the previous year[4] Assets and Equity - The company’s total assets at the end of the reporting period were RMB 1,314.70 million, a decrease of 3.44% from RMB 1,361.58 million at the beginning of the period[5] - The company’s equity attributable to the parent company decreased by 10.75% to RMB 1,064.12 million from RMB 1,192.25 million[5] Research and Development - The company’s R&D expenses for 2025 were RMB 113.69 million, a decrease of 34.68% from RMB 174.03 million in the previous year[7] Product Development - The first-class new drug, Deutetrabenazine soft capsules (Project No: HC-1119), was approved for sale in May 2025, contributing to the significant increase in revenue[8] Market Strategy - The company is in the early stage of commercializing its drug products, requiring significant investment in market expansion and academic promotion activities[7]